Literature DB >> 29843174

Reperfusion Treatment for Acute Pulmonary Embolism.

Rolf P Engelberger1, Nils Kucher2.   

Abstract

Due to the manifold treatment options for the management of acute pulmonary embolism, state-of-the-art management requires risk stratification for choosing the adapted treatment for each patient. Reperfusion therapy is an integral part of therapy for patients with pulmonary embolism at high risk for mortality, but its role in patients with intermediate risk pulmonary embolism is more debated. The largest amount of evidence exists for systemic thrombolysis, which is an efficient therapy, but at the prize of an increased bleeding risk. In recent years, various types of catheter-based reperfusion therapies have been introduced, and evidence is growing that this therapy is as efficient as systemic thrombolysis, but with a more favourable safety profile. Surgical embolectomy remains a good alternative for unstable patients, especially for those with absolute contraindications for thrombolysis or after failed systemic thrombolysis. While the early benefits of reperfusion therapy are well documented, evidence for long-term benefit is still scarce. The scope of this review is to summarize the evidence for the currently available reperfusion therapies in the management of acute pulmonary embolism. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Year:  2018        PMID: 29843174     DOI: 10.1055/s-0038-1641717

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  2 in total

1.  Analysis of pulmonary embolism patients treated with EkoSonic™ endovascular system.

Authors:  Bengü Saylan; Tayfun Çalışkan; Kadir Canoğlu; Ali Ertan Ulucan; Ahmet Turan Yılmaz
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-04-22       Impact factor: 0.332

Review 2.  Management dilemmas in acute ischemic stroke and concomitant acute pulmonary embolism: Case series and literature review.

Authors:  Faddi G Saleh Velez; Jorge G Ortiz Garcia
Journal:  eNeurologicalSci       Date:  2021-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.